Can pretreatment lactate dehydrogenase to albumin ratio predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients?

IF 2 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-03-21 DOI:10.5937/jomb0-43900

Gözde Savaş, Nazan Günel, Ahmet Özet

{"title":"Can pretreatment lactate dehydrogenase to albumin ratio predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients?","authors":"Gözde Savaş, Nazan Günel, Ahmet Özet","doi":"10.5937/jomb0-43900","DOIUrl":null,"url":null,"abstract":"Background: This study aims to evaluate the predictive significance of platelet lymphocyte ratio (PLR), neutrophillymphocyte ratio (NLR), lymphocyte monocyte ratio (LMR), systemic immune-inflammation (SII), prognostic nutritional index (PNI), haemoglobin, albumin, lymphocyte, and platelet (HALP) score and lactate dehydrogenase to albumin ratio (LAR) for pCR in breast cancer with neoadjuvant chemotherapy (NACT).Methods: A total of 121 patients who received NACT between February 2012 and November 2021 were included. LAR, NLR, PLR, MLR, SII, PNI and HALP were calculated using formulas. The cut-off value for markers was obtained by Receiver operating characteristic curve (ROC) analyses. Independent predictive factors for pCR were determined using multivariate regression analysis.Results: The pCR rate was achieved in 31.4% of patients. Median values of NLR, PLR, MLR, SII, PNI and HALP were similar in pCR (+) and pCR (-) (p>0.05). The median LAR value was significantly higher in pCR (+) than in pCR (-) (50.80 vs 42.62, respectively (p=0.002)). The optimal cut-off value of LAR was 46.27. Multivariate analysis showed that LAR ≥46.27 and HER-2 positivity were the independent predictive factors for pCR [OR=2.851 (95% CI=1.142-7.119, P=0.025), OR=3.431 (95% CI= 0.163-10.123, P=0.026), respectively].Conclusions: LAR is a simple, inexpensive, and convenient method for predicting pCR in breast cancer with NACT.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 2","pages":"339-346"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085182/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-43900","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aims to evaluate the predictive significance of platelet lymphocyte ratio (PLR), neutrophillymphocyte ratio (NLR), lymphocyte monocyte ratio (LMR), systemic immune-inflammation (SII), prognostic nutritional index (PNI), haemoglobin, albumin, lymphocyte, and platelet (HALP) score and lactate dehydrogenase to albumin ratio (LAR) for pCR in breast cancer with neoadjuvant chemotherapy (NACT).

Methods: A total of 121 patients who received NACT between February 2012 and November 2021 were included. LAR, NLR, PLR, MLR, SII, PNI and HALP were calculated using formulas. The cut-off value for markers was obtained by Receiver operating characteristic curve (ROC) analyses. Independent predictive factors for pCR were determined using multivariate regression analysis.

Results: The pCR rate was achieved in 31.4% of patients. Median values of NLR, PLR, MLR, SII, PNI and HALP were similar in pCR (+) and pCR (-) (p>0.05). The median LAR value was significantly higher in pCR (+) than in pCR (-) (50.80 vs 42.62, respectively (p=0.002)). The optimal cut-off value of LAR was 46.27. Multivariate analysis showed that LAR ≥46.27 and HER-2 positivity were the independent predictive factors for pCR [OR=2.851 (95% CI=1.142-7.119, P=0.025), OR=3.431 (95% CI= 0.163-10.123, P=0.026), respectively].

Conclusions: LAR is a simple, inexpensive, and convenient method for predicting pCR in breast cancer with NACT.

查看原文本刊更多论文

预处理乳酸脱氢酶/白蛋白比能否预测乳腺癌患者新辅助化疗后病理完全缓解？

背景：本研究旨在评价血小板淋巴细胞比（PLR）、中性淋巴细胞比（NLR）、淋巴细胞单核细胞比（LMR）、全身免疫-炎症反应（SII）、预后营养指数（PNI）、血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分和乳酸脱氢酶与白蛋白比（LAR）对乳腺癌新辅助化疗（NACT）的pCR预测意义。方法：纳入2012年2月至2021年11月期间接受NACT治疗的121例患者。采用公式计算LAR、NLR、PLR、MLR、SII、PNI和HALP。通过受试者工作特征曲线（Receiver operating characteristic curve， ROC）分析得到标记物的截止值。采用多元回归分析确定pCR的独立预测因素。结果：31.4%的患者获得了pCR检出率。NLR、PLR、MLR、SII、PNI和HALP的pCR（+）和pCR（-）中位数相似（p < 0.05）。pCR（+）中位LAR值显著高于pCR (-) (50.80 vs 42.62) （p=0.002）。LAR的最佳临界值为46.27。多因素分析显示，LAR≥46.27和HER-2阳性是pCR的独立预测因素[OR=2.851 (95% CI=1.142 ~ 7.119， P=0.025)， OR=3.431 (95% CI= 0.163 ~ 10.123， P=0.026)]。结论：LAR是一种简单、廉价、方便的NACT预测乳腺癌pCR的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.